Lutetium Lu 177 dotatate
- Generic Name
- Lutetium Lu 177 dotatate
- Brand Names
- Lutathera
- Drug Type
- Small Molecule
- Chemical Formula
- C65H87LuN14O19S2
- CAS Number
- 437608-50-9
- Unique Ingredient Identifier
- AE221IM3BB
- Background
A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dotatate may also be referred to as 177Lu-D...
- Indication
Indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults .
- Associated Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
- Associated Therapies
- -
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 25
- Registration Number
- NCT06663072
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
177Lu-DOTATATE for Recurrent Meningioma
- Conditions
- Interventions
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-03-22
- Target Recruit Count
- 135
- Registration Number
- NCT06326190
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 10
- Registration Number
- NCT06122610
- Locations
- 🇺🇸
University of Wisconsin - Madison, Madison, Wisconsin, United States
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT06016855
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial
- Conditions
- Interventions
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT05773274
- Locations
- 🇺🇸
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 94
- Registration Number
- NCT05724108
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
- Conditions
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT05691465
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT05687123
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Memorial Hospital East, Shiloh, Illinois, United States
🇺🇸Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 18
- Registration Number
- NCT05583708
- Locations
- 🇺🇸
Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 198
- Registration Number
- NCT05247905
- Locations
- 🇺🇸
Advocate Outpatient Center - Aurora, Aurora, Illinois, United States
🇺🇸Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States
🇺🇸MU Health Care Goldschmidt Cancer Center, Jefferson City, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.